Double blind, randomized placebo control study to evaluate efficacy and safety of EMTACT, a Homeopathic drug in the management of Recurrent Upper and Lower Respiratory Tract affections

Homeopathy India Private Limited0 个研究点目标入组 148 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•Having episodes of Recurrent Upper and/or Lower Respiratory Tract affections at least four times in previous six months, for at least for one day at a time.
•At least one symptom from at least two of the location group symptoms, such as
•Nasal symptoms (sneezing, running nose, nose block)
•Throat symptoms (sore throat),
•Bronchial symptoms (cough, wheezing)
•Head and sinus symptoms (headache, face-ache)
•General symptoms (fever, fatigue, low appetite)
•Be willing to refrain from taking nasal decongestants, antihistamines or cough/cold preparations, antibiotics and homeopathic medicines during the trial period, unless symptoms are severe (define).
•Written informed consent by patient, by child (assent form) and guardians of patient has been informed about the study and has given her/his written informed consent.
•In the opinion of the investigator, able to comply with the requirements of the protocol

•Ongoing treatment for tuberculosis or untreated tuberculosis (to rule out by CBC, ESR, x-ray chest)
•Any clinically significant medical condition or abnormality, which, in the opinion of the investigator, might compromise the safety of the subject or which might interfere with the study.
•Homeopathic treatment for any chronic disease within l month.
•Immuno-compromised patient(Known cases of Tuberculosis, HIV, Cancer)
•Females who are pregnant or planning to become pregnant or lactating mother.
•Patients who are scheduled to receive any other investigational drug during the course of the study

发起方

Homeopathy India Private Limited